Compound Libraries

Comprises 81 highly selective inhibitors of various kinases

Comprises 171 modulators of various aspects of cancer cell metabolism

A unique collection of 2863 approved drugs for high throughput screening (HTS) and high content screening (HCS);

3158 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 344 protease and proteasome inhibitors for research in chemical genomics, and drug screening;

A unique collection of 80 microtubule-targeted compounds can be used in HTS and HCS;

80 well-chosen unique AMPK-targeted small molecules；

Well-chosen 960 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs;

A unique collection of 425 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with PI3K/Akt/mTOR signaling;